Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Boolean model of growth signaling, cell cycle and apoptosis predicts the molecular mechanism of aberrant cell cycle progression driven by hyperactive PI3K.

Sizek H, Hamel A, Deritei D, Campbell S, Ravasz Regan E.

PLoS Comput Biol. 2019 Mar 15;15(3):e1006402. doi: 10.1371/journal.pcbi.1006402. eCollection 2019 Mar.

2.

Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA.

Cell Cycle. 2011 Apr 15;10(8):1295-302. Epub 2011 Apr 15.

PMID:
21474997
3.

A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells.

Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, Lee KS.

J Biol Chem. 2002 Aug 30;277(35):32282-93. Epub 2002 May 28.

4.

Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.

Mao Y, Xi L, Li Q, Cai Z, Lai Y, Zhang X, Yu C.

Oncol Rep. 2016 Jul;36(1):49-56. doi: 10.3892/or.2016.4820. Epub 2016 May 18.

5.
6.

High mitotic activity of Polo-like kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells.

Lera RF, Burkard ME.

J Biol Chem. 2012 Dec 14;287(51):42812-25. doi: 10.1074/jbc.M112.412544. Epub 2012 Oct 27.

7.

Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies.

Wachowicz P, Fernández-Miranda G, Marugán C, Escobar B, de Cárcer G.

Bioessays. 2016 Jul;38 Suppl 1:S96-S106. doi: 10.1002/bies.201670908.

PMID:
27417127
8.

Regulation and Role of Store-Operated Ca2+ Entry in Cellular Proliferation.

Hodeify R, Yu F, Courjaret R, Nader N, Dib M, Sun L, Adap E, Hubrack S, Machaca K.

In: Kozak JA, Putney JW Jr., editors. Calcium Entry Channels in Non-Excitable Cells. Boca Raton (FL): CRC Press/Taylor & Francis; 2018. Chapter 12.

9.

Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1.

Liu X, Zhou T, Kuriyama R, Erikson RL.

J Cell Sci. 2004 Jul 1;117(Pt 15):3233-46. Epub 2004 Jun 15.

10.

The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.

Yuan C, Wang L, Zhou L, Fu Z.

Cell Cycle. 2014;13(5):807-19. doi: 10.4161/cc.27727. Epub 2014 Jan 9.

11.

Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.

Raab M, Krämer A, Hehlgans S, Sanhaji M, Kurunci-Csacsko E, Dötsch C, Bug G, Ottmann O, Becker S, Pachl F, Kuster B, Strebhardt K.

Mol Oncol. 2015 Jan;9(1):140-54. doi: 10.1016/j.molonc.2014.07.020. Epub 2014 Aug 11.

12.

Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T, Liu X.

Cancer Res. 2014 Nov 15;74(22):6635-47. doi: 10.1158/0008-5472.CAN-14-1916. Epub 2014 Sep 24.

14.

Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.

Bu Y, Yang Z, Li Q, Song F.

Oncology. 2008;74(3-4):198-206. doi: 10.1159/000151367. Epub 2008 Aug 20.

PMID:
18714168
15.

DNA-PKcs associates with PLK1 and is involved in proper chromosome segregation and cytokinesis.

Huang B, Shang ZF, Li B, Wang Y, Liu XD, Zhang SM, Guan H, Rang WQ, Hu JA, Zhou PK.

J Cell Biochem. 2014 Jun;115(6):1077-88. doi: 10.1002/jcb.24703.

PMID:
24166892
16.

Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.

Chou YS, Yen CC, Chen WM, Lin YC, Wen YS, Ke WT, Wang JY, Liu CY, Yang MH, Chen TH, Liu CL.

Int J Oncol. 2016 Mar;48(3):1187-94. doi: 10.3892/ijo.2016.3352. Epub 2016 Jan 20.

PMID:
26794530
17.

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA Jr, Cheung M.

Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.

18.

PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor.

Bucur O, Stancu AL, Muraru MS, Melet A, Petrescu SM, Khosravi-Far R.

Discoveries (Craiova). 2014 Apr-Jun;2(2). pii: e16.

19.

MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.

Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX.

BMC Cancer. 2012 Nov 14;12:519. doi: 10.1186/1471-2407-12-519.

20.

O-GlcNAcylation enhances the invasion of thyroid anaplastic cancer cells partially by PI3K/Akt1 pathway.

Zhang P, Wang C, Ma T, You S.

Onco Targets Ther. 2015 Nov 9;8:3305-13. doi: 10.2147/OTT.S82845. eCollection 2015.

Supplemental Content

Support Center